Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Contact information


mathieu.fischer@paediatrics.ox.ac.uk

Mathieu Fischer

Research Assistant

Now I take part in a preclinical project utilizing peptide delivered oligonucleotides for the treatment of Myotonic Dystrophy type 1 (DM1) under the supervision of Dr Miguel Varela-Muino. I am responsible for assisting in the day-to-day execution of the project and take care of the animal experiments.

The research project will evaluate antisense oligonucleotides for the therapy of DM1, the most common form of muscular dystrophy in adults and a genetic neuromuscular disease characterized by progressive muscle degeneration. There is currently no disease-modifying therapy for DM1. Our therapeutic solution is an advanced peptide-conjugated antisense oligonucleotide that permits highly effective systemic delivery to all affected tissues. Our project aims to identify and optimize a lead compound suitable for clinical development in the future.